[{"orgOrder":0,"company":"Opterion Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"OPT101","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Opterion Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opterion Health \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Opterion Health \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Opterion Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : OPT101 is a novel non-glucose-based osmotic agent bringing much-needed new therapy options to patients with renal failure.

                          Product Name : OPT101

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 17, 2025

                          Lead Product(s) : OPT101

                          Therapeutic Area : Nephrology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank